Pfizer vaccine: an immunologist explains

Pfizer and BioNTech have concluded the Phase 3 trial of their coronavirus vaccine. The results appear to show an efficacy rate of 95%, and the developers hope to win FDA approval as soon as possible. This vaccine - a promising hope for many - works via a new methiod that's never been tried before in humans. Chris Smith asked Cambridge University immunologist Clare Bryant for her reaction... Like this podcast? Please help us by supporting the Naked Scientists